Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/120730
Author(s): Moreno, PM
Pêgo, AP
Title: Therapeutic antisense oligonucleotides against cancer: Hurdling to the clinic
Publisher: Frontiers Media
Issue Date: 2014
Abstract: Under clinical development since the early 90's and with two successfully approved drugs (Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet delivered a clinical drug to the market in the cancer field. Whilst many pre-clinical data has been generated, a lack of understanding still exists on how to efficiently tackle all the different challenges presented for cancer targeting in a clinical setting. Namely, effective drug vectorization, careful choice of target gene or synergistic multi-gene targeting are surely decisive, while caution must be exerted to avoid potential toxic, often misleading off-target-effects. Here a brief overview will be given on the nucleic acid chemistry advances that established oligonucleotide technologies as a promising therapeutic alternative and ongoing cancer related clinical trials. Special attention will be given toward a perspective on the hurdles encountered specifically in the cancer field by this class of therapeutic oligonucleotides and a view on possible avenues for success is presented, with particular focus on the contribution from nanotechnology to the field.
Subject: Antisense
Cancer
Nanomedicine
Oligonucleotides
Therapeutics
URI: https://hdl.handle.net/10216/120730
Source: Frontiers in Chemistry, vol. 2:87
Related Information: info:eu-repo/grantAgreement/FCT/5876-PPCDTI/115124/PT
info:eu-repo/grantAgreement/FCT/5876-PPCDTI/116372/PT
info:eu-repo/grantAgreement/FCT/COMPETE/132934/PT
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
License: https://creativecommons.org/licenses/by/4.0/
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
fchem201400087.pdf844.18 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons